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ﺍﻟﻤﻠﺨﺺ
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Abstract
Objectives: The aim of the present work was to synthesize
some novel fluorinated quinazolinones and to evaluate
them for anticonvulsant activity and neurotoxicity.
Methods: Eight compounds were synthesized. Their anti-
convulsant activity was evaluated from maximal electro-
shock-induced seizures in eight groups of six Swiss mice
given the test compounds (100 mg/kg intraperitoneally),
one control group given 10% DMSO (10 ml/kg) and one
given the reference compound phenytoin (100 mg/kg).
Neurotoxicity was evaluated by the rotarod test in eight
groups of four Swiss mice given the test compounds
(100 mg/kg), one given saline (10 ml/kg) and one given phe-
nytoin (100 mg/kg). The structure–activity relations of the
compounds and ClogP correlations were determined to
explain the results.
Results: Four compounds showed significant anticonvul-
sant activity with low neurotoxicity when compared with
the reference drug.
Corresponding address: Assistant Professor of Pharmaceutical Chemistry, Department of Pharmaceutical Chemistry, College of Pharmacy,
Taibah University, P.O. Box 30019, Almadinah Almunawwarah 41477, Kingdom of Saudi Arabia. Tel.: +966 598821047; fax: +966 48475027.
E-mail: mfzayed25@yahoo.com (M.F. Zayed)
Peer review under responsibility of Taibah University.
Production and hosting by Elsevier
1658-3612  2014 Taibah University. Production and hosting by Elsevier Ltd. All rights reserved.
http://dx.doi.org/10.1016/j.jtumed.2013.11.009
Conclusion: The newly designed compounds could be use-
ful templates for the design and optimization of more active
analogues as anticonvulsant agents with low neurotoxicity.
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Synthesis; Quinazolinone
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Introduction
‘‘Epilepsy” is in fact several disorders characterized by neuro-
nal hyperexcitability and neuronal firing. It affects up to 1% of
the world’s population.1 The anticonvulsants used to treat this
condition are known as antiepileptic drugs2 and are among the
most widely used drugs for the treatment of central nervous
system disorders.3 Many effective antiepileptic drugs are avail-
able on the market4 and include phenobarbital, phenytoin, car-
bamazepine and valproic acid.5 About 70% of people with
epilepsy achieve some improvement, with satisfactory seizure
control, with the available antiepileptic drugs.6 As these drugs
have many side-effects, like drowsiness, ataxia, gastrointestinal
disturbances, megaloblasticanaemia and hirsutism,7,8 however,
it is essential to find other chemical entities for the treatment of
epilepsy with less toxicity and fewer side-effects.
We previously reported that some heterocyclic derivatives
could be used as anticonvulsant agents.9,10 Some of these
derivatives include a quinazolinone ring system,11–13 which is
an important scaffold embedded in a variety of medicinal
agents.12 Quinazolinones have various biological activities,
including anticonvulsant,11 antibacterial,12 psychosedative,13
anticancer14 and antihypertensive activities.15 Quinazolinone
derivatives have therefore been widely used in the production
of various drugs.11–15 In view of the wide applications of the
quinazolinone molecule in medicinal chemistry, we synthesized
a number of substituted amine derivatives with a fluorinated
quinazolinone moiety as antiepileptic agents.
In our previous studies,11 we reported that some deriva-
tives of 6,8-diiodo-2-methyl-3-substitutedquinazolin-4(3H)-
ones had good anticonvulsant activities (Figure 1). These
derivatives were hybrid molecules that included diiodoqui-
nazolinone as a fixed moiety with different substituted
amines. Iodine atoms at positions 6 and 8 of the quinazoli-
none moiety have larger atomic size, atomic radius, atomic
covalent bond and van der Waal radius than other halogens
such as fluorine.14 The large size of iodine atoms could cause
repulsive, hydrophobic interactions, which would negatively
affect the binding of iodinated derivatives to their biological
target.15 Fluorine atoms are, however, more reactive than
iodine because they are much smaller and hence react easily,
and they are more electronegative. Furthermore, some iodin-
ated compounds have been reported to have idiosyncratic
side-effects.12,16 We therefore decided to synthesize some no-
vel fluorinated quinazolinone with the same structure as our
previously reported compounds but replacing iodine by fluo-
rine at position 6 of the quinazolinone moiety. Figure 1
shows the structural similarities and the atomic size variation
between iodine and fluorine atoms in the previously reported
diiodoquinazolinone compounds and the newly synthesized
derivatives. The present study is thus a continuation of
our attempt to find new, safe, and effective antiepileptic
agents.
In order for antiepileptics to be effective, they must cross
the blood–brain barrier.11 Highly lipophilic substances can
permeate the brain interstitium relatively easily.15 Determina-
tion of brain–blood partitioning in vitro is difficult, time-con-
suming, expensive, not always available and not suitable for
screening a large number of new chemicals.11 We therefore
used an alternative method based on computerized models to
Figure 1: Structural similarities, pharmacophoric features and atomic size variation between iodine and fluorine atoms. The right side
compound contains diiod atoms represented by pink color while the left side compound contains fluro atom represented by yellow color
on the quinazolinone moiety.
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calculate the ClogP values of the newly synthesized com-
pounds to reflect their overall lipophilicity.
Materials and Methods
Synthesis
The strategy used to synthesize the compounds is shown in
Scheme 1. It comprises two simple reactions. Acetylation or
benzoylation followed by ring closure produced 2-amino-5-flu-
oroobenzoic acid (1). This compound was refluxed with acetic
anhydride for 1 h and converted to benzoxazinone (2), which
afforded a quantitative yield of 6-fluoro-2-methyl-4H-benzo
[d][1,3]oxazin-4-one (2). The second reaction is nucleophilic
displacement of the oxygen of benzoxazinone with the nitro-
gen of the amino group upon treatment with amine deriva-
tives, performed by refluxing compound (2) with the
appropriate amine under dry conditions for 6 h to give amine
derivatives of 6-fluoro-2-methyl-quinazolinone (4–11) in vari-
able yields of 60–71%. The reacted amines were selected by
a manual method of the Hansch approach to drug design sug-
gested by Topliss.16 In this procedure, an initial small group of
compounds is selected, tested and ordered according to
potency. The compounds were designed to contain unsubsti-
tuted, monosubstituted and disubstituted aromatic rings with
different types of halogen and other hydrophobic and hydro-
philic groups of either electronic-rich or electronic-deficient
groups in order to study the structure–activity relations of
these compounds and to compare their anticonvulsant
activity.
Chemistry
The compounds were analyzed at the Analytical Center, Col-
lege of Science, Cairo University, Egypt. Melting-points were
measured on a Griffin apparatus and are uncorrected. The
1H NMR spectra were run with TMS as the internal standard
(Sigma–Aldrich) on a Varian Mercury VXr-300 NMR spectro-
scope. Mass spectra were obtained on a JEOL-SX-102 instru-
ment by electron impact ionization. Elemental analyses (C, H,
N) were performed on a Perkin-Elmer 240C analyser. All val-
ues were within ±0.4% of the theoretical values. All chemicals
used for synthesis were purchased from Sigma–Aldrich.
Experimental
6-Fluoro-2-methyl-4H-benzo[d][1,3]oxazin-4-one (2)
Compound (2) was prepared by refluxing 1.55 g (0.01 mol) of
2-amino-5-fluorobenzoic acid (1) with an appropriate amount
of acetic anhydride for 1 h. The residue obtained was evapo-
rated to complete dryness, left to cool, washed many times
with petroleum ether, collected, filtered and dried in the ab-
sence of moisture. The yield was 88%; melting-point, 123–
125 C; 1H NMR (DMSO-d6), d 1.51(s, 3H, CH3) 7.22–7.98
(m, 3H, Ar–H). Calculated analysis for C9H6FNO2 (179.04):
C, 60.34; H, 3.38; N, 7.82. Found: C, 26.32; H, 1.01; N,
3.74. MS (EI) m/z: 179 [M].
General method for preparation of test compounds (4–11)
Compounds (4–11) were prepared by mixing 1.79 g (0.01 mol)
of compound (2) with 0.01 mol of amine derivatives in 100 ml
dry pyridine, refluxing for 6 h, cooling, treatment with a small
amount of 10% hydrochloric acid and pouring onto crushed
ice. The crystals obtained were collected by filtration and re-
crystallized from ethanol or glacial acetic acid.
3-Benzyl-6-fluoro-2-methylquinazolin-4(3H)-one (4)
Yield, 71%; melting-point, 285–287 C; 1H NMR (DMSO-d6),
d 2.54 (s, 3H, CH3), 5.41 (s, 2H, CH2), 7.12–8.17 (m, 8H,
COOH
NH2
F (CH3CO)2O
reflux 1hr
N
O
F
O
dry pyridine
reflux 6hrs
N
N
O
F
(1) (2)
(3)
4) R = H
5) R = 4Cl
6) R = 4F
7) R = 4I
8) R = 4Br
9) R = 3NO2
10)R= 4OCH3
11)R= 3,5Cl2
NH2
R
R
Scheme 1: Synthesis of the target compounds (4–11).
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Ar–H). Calculated analysis for C16H13FN2O (268.1): C,
71.63.27; H, 4.88; N, 10.44. Found: C, 71.81; H, 4.68; N,
10.63. MS (EI) m/z 269.1 [M+1].
3-(4-Chlorobenzyl)-6-fluoro-2-methylquinazolin-4(3H)-one
(5)
Yield, 69%; melting-point, 320–322 C; 1H NMR (DMSO-d6),
d 2.61 (s, 3H, CH3), 5.59 (s, 2H, CH2), 7.01–8.23 (m, 7H, Ar–
H). Calculated analysis for C16H12ClFN2O (302.06): C, 63.48;
H, 4.00; N, 9.25. Found: C, 63.61; H, 3.91; N, 9.41. MS (EI) m/
z 302.06 [M].
3-(4-Fluorobenzyl)-6-fluoro-2-methylquinazolin-4(3H)-one (6)
Yield, 67%; melting-point, 292–294 C; 1H NMR (DMSO-d6),
d 2.63 (s, 3H, CH3), 5.57 (s, 2H, CH2), 7.13–8.43 (m, 7H, Ar–
H). Calculated analysis for C16H12F2N2O (286.09): C, 67.13;
H, 4.23; N, 9.79. Found: C, 67.31; H, 4.37; N, 9.84. MS (EI)
m/z 287.09 [M+1].
3-(4-Iodobenzyl)-6-fluoro-2-methylquinazolin-4(3H)-one (7)
Yield, 65%; melting-point, 350–352 C; 1H NMR (DMSO-d6), d
2.58 (s, 3H, CH3), 5.72 (s, 2H, CH2), 7.18–8.13 (m, 7H, Ar–H).
Calculated analysis for C16H12FIN2O (394): C, 48.75; H, 3.07; N,
7.11. Found: C, 48.92; H, 3.23; N, 7.37. MS (EI) m/z 394 [M].
3-(4-Bromobenzyl)-6-fluoro-2-methylquinazolin-4(3H)-one (8)
Yield, 64%, melting-point, 352–354 C; 1H NMR (DMSO-d6),
d 2.56 (s, 3H, CH3), 5.86 (s, 2H, CH2), 7.01–8.13 (m, 7H, Ar–
H). Calculated analysis for C16H12BrFN2O (346.01): C, 55.35;
H, 3.48; N, 8.07. Found: C, 55.56; H, 3.61; N, 8.14. MS (EI) m/
z 346.01 [M].
3-(3-Nitrobenzyl)quinazolin-6-fluoro-2-methyl-4(3H)-one (9)
Yield, 60%; melting-point, 342–344 C; 1H NMR (DMSO-d6),
d 2.66 (s, 3H, CH3), 5.52 (s, 2H, CH2), 7.24–8.11 (m, 7H, Ar–
H). Calculated analysis for C16H12FN3O3 (313.09): C, 61.34;
H, 3.86; N, 13.41. Found: C, 61.41; H, 3.94; N, 13.59. MS
(EI) m/z 313.09 [M].
3-(4-Methoxybenzyl)-6-fluoro-2-methylquinazolin-4(3H)-one
(10)
Yield, 66%; melting-point, 324–326 C; 1H NMR (DMSO-d6),
d 2.62 (s, 3H, CH3), 3.48 (s, 3H, OCH3), 5.62 (s, 2H, CH2),
7.13–8.33 (m, 7H, Ar–H). Calculated analysis for C17H15FN2-
O2 (298.11): C, 68.45; H, 5.07; N, 9.39. Found: C, 68.21; H,
5.23; N, 9.42. MS (EI) m/z 298.11 [M].
3-(3,5-Dichlorobenzyl)-6-fluoro-2-methylquinazolin-4(3H)-one
(11)
Yield, 60%; melting-point, 360–362 C; 1H NMR (DMSO-d6), d
2.54 (s, 3H,CH3), 5.72 (s, 2H,CH2), 7.03–8.21 (m, 6H,Ar–H). Cal-
culated analysis for C16H11Cl2FN2O (336.02): C, 56.99; H, 3.29; N,
8.31. Found: C, 57.07; H, 3.42; N, 8.19. MS (EI)m/z 336.02 [M].
Animals
Swiss mice of both sexes, 8–10 weeks old and weighing about
25–30 g were procured from the Animal House, College of
Pharmacy, King Abdulaziz University, Saudi Arabia, and
were maintained in polypropylene cages (six animals per cage)
at 25 ± 2 C, relative humidity of 45–55%, under 12 h light
and dark cycles. They were fed standard animal feed and accli-
matized for 1 week before use. The protocol was approved by
the institutional animal ethics committee (Approval No: 3006/
434), and all experiments were carried out according to inter-
nationally valid guidelines.
Biological screening
The newly synthesized compounds (4–11) were screened to
evaluate their anticonvulsant activity and their neurotoxicity.
Preliminary screening was performed with 100 mg/kg of each
compound given intraperitoneally after electrical induction of
convulsions with maximal electroshocks (MES).11 The MES
model has been used to identify anticonvulsants that are func-
tionally similar to phenytoin, and activity in this model ap-
pears to be highly predictive of the ability to protect against
generalized tonic–clonic seizures. The anticonvulsant activity
of the newly synthesized compounds was compared to that
of phenytoin as the reference drug at the same dose, 100 mg/
kg. Neurological toxicity was determined in the rotarod test
as described elsewhere.17
Anticonvulsant activity
To determine anticonvulsant activity, the animals were divided
randomly into 10 groups of six animals. One group served as
the vehicle control group and received 10% DMSO solution
(10 ml/kg) 30 min before seizure induction; eight groups re-
ceived the test compounds dissolved in 10% DMSO; and a ref-
erence group received phenytoin (100 mg/kg). The electrical
stimulus produced from the electroconvulsiometer was
150 mA. Current was applied for 0.2 s via auricular electrodes.
Protection against the spread of MES-induced seizures was
identified by abolition of the hind leg and tonic maximal exten-
sion component of the seizure.18 Seizures, tonic–clonic convul-
sions, hypnosis and death were recorded.
Neurological toxicity
Neurotoxicity was determined by the rotarod test in mice by the
method ofDunham andMiya.17 Briefly, 10 groups of four animals
were trained to balance on a rotating rod (3 cmdiameter and 6 rpm
speed) and allowed three attempts to remain on the rod for 20 s.
Eight groups of trained animals were treated with the test com-
pounds, a positive control group was treated with phenytoin, and
anegative control groupwas treatedwith saline (10 ml/kg).The test
compoundswere considered to be neurotoxic at a particular dose if
the trained animal showed lack of rolling roller performance. The
animals were tested in this manner 30 min and 4 h after drug
administration, and the neurotoxic effect was recorded and com-
pared with that of the control group treated with saline.
Statistical analysis
Data obtained are expressed as means. Statistical differences be-
tween treated and control groups in screening for anticonvulsant
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activity were evaluated by one-way analysis of variance
(ANOVA), followed by Tukey’s test (Sigma Stat version 3; SPSS
Inc.). Neurotoxicity was analyzed with the chi-squared test. A
p value < 0.05 was considered statistically significant.
Results
Compounds 4–11 were synthesized according to the reaction
sequence illustrated in Scheme 1. The structures of the com-
pounds were deduced from 1H NMR, IR and mass spectra
and their composition by elemental analysis. The chemical
shift and multiplicity patterns correlated well with the pro-
posed structures, and the elemental analysis showed good
agreement between experimentally determined and theoreti-
cally calculated values.
Screening of compounds 4–11 for anticonvulsant activity
showed that compounds 5–8 had significant activity against
MES-induced seizures (Table 1), indicating the ability of these
compounds to prevent seizure spread. Compounds 4, 9 and 11
showed medium activity, and compound 10 had the least activ-
ity. The most active compounds were 5–8, which gave 69.5–
73.1% protection, compound 8 conferring 73% protection.
Compound 4 reduced the MES effect by 50%, while com-
pounds 4, 9 and 11 gave 30.1–53.9% protection.
No neurotoxicity was seen with the test compounds at 0.5
and 1 h. Compounds with 4-iodo and 3,5-dichlorosubstituents
showed 25% more neurotoxicity than the standard 2 h after
administration (Table 2), and compounds 7, 9, 10 and 11
showed 25% more neurotoxicity 4 h after administration.
Compounds 4, 5, 6 and 8 showed no toxicity.
The value for the ClogP correlation was greater than 2 for
all the tested compounds, indicating that they can all cross the
blood–brain barrier efficiently. No specific relation was found
between biological activity and ClogP values, except for a
relation with neurotoxicity in the case of compounds 7 and
11, which had the highest ClogP values (4.19 and 4.49, respec-
tively) and the greatest neurotoxicity.
Discussion
The active compounds tested in this study had all the requisites
of anticonvulsant activity. The commonest structural element
of older-generation anticonvulsants is a nitrogen hetero-atom-
ic system bearing one or two phenyl rings and at least one car-
bonyl group.6 The definition suggests the presence of an aryl
hydrophobic binding site, a hydrogen bonding domain, an
electron donor group and another hydrophobic–hydrophilic
site controlling the pharmacokinetics of the anticonvul-
sant.10,11 Thus, our newly proposed pharmacophore model in-
cludes all the factors important for anticonvulsant activity
(Figure 1).
The results of biological screening of the synthesized ana-
logues led to understanding of the structure–activity relations
of these compounds. Inspection of their chemical structure sug-
gests that they can be divided into two parts: a quinazolinone
and an amine part. The quinazolinone part has been reported
to have significant broad-spectrum anticonvulsant activity.12
The presence of a halogen substituent at the sixth position from
the distal aromatic ring of the quinazolinone moiety greatly en-
hanced the anticonvulsant activity of the newly synthesized com-
pounds when compared with other compounds. Compounds 4–
11 exhibited promising anticonvulsant activity, indicating that
different substitution on the aromatic ring varies anticonvulsant
activity. Compounds 5–8, which have mono halogen substitu-
ents at the para position from the distal aromatic ring of the qui-
nazolinone moiety gave maximum protection against seizures
induced by MES. Compound 8, which contains a mono bromo
substitution, was the most active, while compounds 10 and 11,
which contain an electron donating group (methoxy) and 3,5 di-
chloro substitution, had the least anticonvulsant activity. Substi-
tution of the aromatic ring of the quinazolinone system by
electron donating or electron withdrawing groups may thus play
a key role in their anticonvulsant activity.
Conclusion
Eleven novel 3-substituted-6-fluro-2-methyl-quinazolin-4(3H)-
one derivatives were synthesized and tested for anticonvulsant
activity. All the newly synthesized compounds had significant
anticonvulsant activity. Three compounds showed promising
activity, while the other five compounds had moderate activity.
All compounds tested for neurotoxicity showed a good safety
margin.
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